Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1210 - Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study


19 Dec 2015


Poster presentation 1


Xianjun Yu


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


X. Yu1, L. Shen2, J. Hao3, L. Wang4, H. Pan5, G. Han6, J. Xu7, Y. Zhang8, S. Yang9, J. Ying10, M. Li11, D. Begic12, B. Lu12, R. Xu13

Author affiliations

  • 1 Department Of Pancreatic & Hepatobiliary Surgery, Shanghai Cancer Center Fudan University, 200032 - Shanghai/CN
  • 2 Oncology, Peking University Cancer Hospital-Beijing Cancer Hospital, haidian - Beijing/CN
  • 3 Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN
  • 4 Oncology, 1st Shanghai People's Hospital, Shanghai/CN
  • 5 Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou/CN
  • 6 Oncology, Xijing Hospital, 4th Military Medical University, Xi'an/CN
  • 7 Oncology, 307th Hospital of PLA (AMMS China), Beijing/CN
  • 8 Oncology, 1st Hospital Harbin Institute of Hematology, Harbin/CN
  • 9 Oncology, Henan Provincial Anti-Cancer Hospital, Zhengzhou/CN
  • 10 Oncology, Zhejiang Cancer Hospital, Hangzhou/CN
  • 11 Biostatistics, Celgene, Summit/US
  • 12 Cr&d, Celgene, Summit/US
  • 13 Oncology, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN


Abstract 1210


Pancreatic cancer is the ninth most common cancer in China, with an estimated 88,500 new cases in 2012. In the global phase III MPACT trial (N = 861), nab-P + Gem demonstrated significantly better overall survival (OS; median: 8.7 vs 6.6 months; HR 0.72; P < 0.001) and overall response rate (ORR; 23% vs 7%; P < 0.001) than Gem alone as first-line treatment for pts with MPC. This phase II bridging study was designed to complement the MPACT trial by evaluating efficacy and safety of nab-P + Gem in Chinese pts with MPC.


This was a 3-part sequential study. Part 1 (dose evaluation) examined safety of nab-P 125 mg/m2 + Gem 1000 mg/m2 on days 1, 8, and 15 every 4 weeks (qw 3/4) in 10 pts. Part 2 (1-arm efficacy evaluation) examined efficacy by the Simon optimal 2-stage design. If there were > 2 responses in 28 pts in stage 1, an additional 54 pts would be evaluated in stage 2. The study would be completed if > 9 responses were observed. If after stage 1 or 2, an insufficient number of responses were observed, part 3 (randomized 2-arm design) would be triggered to compare nab-P + Gem vs Gem alone. The primary endpoint was ORR. Secondary endpoints included duration of response (DOR), OS, and safety.


Eighty-three pts were enrolled. Median age was 57.0 years; 19% were aged > 65 years; 70% had a baseline Karnofsky performance status (KPS) of 90 - 100, and 30% had a KPS of 70 - 80. All pts received nab-P 125 mg/m2 + Gem 1000 mg/m2 qw 3/4. Combining results for stages 1 and 2, 29 pts had an objective response (ORR = 35%) by independent assessment, median DOR was 8.9 months (95% CI, 6.01 - 8.94), and median OS was 9.2 months (95% CI, 7.6 - 11.10). The most common grade ≥ 3 adverse events were neutropenia (37%), leukopenia (31%), fatigue (14%), and thrombocytopenia (13%). Grade ≥ 3 peripheral neuropathy occurred in 7% of pts. The ORR endpoint for part 2 was met, so the study did not progress to part 3.


nab-P + Gem demonstrated promising efficacy in Chinese pts with MPC. The OS and ORR were slightly better than those of the phase III MPACT trial. No new safety signals were identified.

Clinical trial identification



M. Li, D. Begic, B. Lu: Celgene employee and stock owner. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings